The bedtime administration leverages the GH release during sleep cycles
Find out what a recent study showed in the Concerns and Cautions section of our Protein Supplements Review
Am J Phys Heart Circ Phys 304:H1085H1093 Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS (2010) VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model
doi:10.3945/an.117.015628
Contraindications and Precautions Do NOT use AOD-9604 if you: Are pregnant, trying to conceive, or breastfeeding (no safety data in pregnancy/lactation) Have active cancer or history of malignancy (peptide effects on existing cancer unknown) Are under 18 years of age (pediatric safety not established) Have known hypersensitivity to peptides or benzyl alcohol (in bacteriostatic water) Have severe kidney or liver disease without physician clearance Use with caution and enhanced monitoring if you have: Diabetes or glucose metabolism disorders (monitor blood sugar closely despite no expected impact) Cardiovascular disease (comprehensive cardiac evaluation recommended) Thyroid disorders (monitor thyroid function during therapy) History of migraines (may increase headache frequency in susceptible individuals) Drug Interactions Limited formal drug interaction studies exist for AOD-9604
So a 0.25 mg dose = 0.25 ml = 25 units on a U-100 insulin syringe
